Are there any remedies for macular degeneration

What drugs are used to treat wet AMD?

Li J, Xu J, Chen Y, Zhang J, Cao Y, Lu P. Efficacy Comparison of Intravitreal Anti-VEGF Therapy for Three Subtypes of Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis. J Ophthalmol 2018; 2018: 1425707.

Low A, Faridi A, Bhavsar KV, Cockerham GC, Freeman M, Fu R et al. Comparative effectiveness and harms of intravitreal antivascular endothelial growth factor agents for three retinal conditions: a systematic review and meta-analysis. Br J Ophthalmol 2019; 103 (4): 442-451.

Moja L, Lucenteforte E, Kwag KH, Bertele V, Campomori A, Chakravarthy U et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2014; (9): CD011230.

Nguyen CL, Oh LJ, Wong E, Wei J, Chilov M. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials. BMC Ophthalmol 2018; 18 (1): 130.

Sarwar S, Clearfield E, Soliman MK, Sadiq MA, Baldwin AJ, Hanout M et al. Aflibercept for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2016; (2): CD011346.

Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2019; (3): CD005139.

Thulliez M, Angoulvant D, Pisella PJ, Bejan-Angoulvant T. Overview of Systematic Reviews and Meta-analyzes on Systemic Adverse Events Associated With Intravitreal Anti-Vascular Endothelial Growth Factor Medication Use. JAMA Ophthalmol 2018; 136 (5): 557-566.

Ueta T, Noda Y, Toyama T, Yamaguchi T, Amano S. Systemic vascular safety of ranibizumab for age-related macular degeneration: Systematic review and meta-analysis of randomized trials. Ophthalmology 2014; 121 (11): 2193-2203.

IQWiG health information is intended to help understand the advantages and disadvantages of important treatment options and health care offers.

Whether one of the options we have described actually makes sense in individual cases can be clarified in a conversation with a doctor. Gesundheitsinformation.de can support the discussion with doctors and other experts, but not replace it. We do not offer individual advice.

Our information is based on the results of high quality studies. They are created by a team of authors from medicine, science and the editorial team and reviewed by experts outside IQWiG. We describe in detail in our methods how we develop our texts and keep them up to date.